Pharmacokinetic-pharmacodynamic modeling of the coexistence of stimulatory and sedative components for midazolam

European Journal of Pharmacology

Volumn 346, Issue 2-3, 1998, Pages 131-144

  Lau, Chyan E ^a   Wang, Yunxia ^a   Ma, Fang ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Benzodiazepine; Midazolam; Pharmacokinetic pharmacodynamic modeling; Sedative effect; Stimulatory effect; Timing performance

Indexed keywords

MIDAZOLAM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG EFFECT; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SEDATION;

ALGORITHMS; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONDITIONING, OPERANT; HALF-LIFE; HYPNOTICS AND SEDATIVES; INDICATORS AND REAGENTS; MALE; MIDAZOLAM; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032502629     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00065-X     Document Type: Article

References (36)

1. Boisse N.R., Quaglietta N., Samoriski G.M., Guarino J.J. Tolerance and physical dependence to a short-acting benzodiazepine, midazolam. J. Pharmacol. Exp. Ther. 252:1990;1125-1133.
2. Bornemann L.D., Min B.H., Crews T., Rees M.M.C., Blumenthal H.P., Colburn W.A., Patel I.H. Dose dependent pharmacokinetics of midazolam. Eur. J. Clin. Pharmacol. 29:1985;91-95.
3. Burke T.F., Miller L.G., Moerschbaecher J.M. Acute effects of benzodiazepines on operant behavior and in vivo receptor binding in mice. Pharmacol. Biochem. Behav. 48:1994;69-76.
4. Dayneka N.L., Garg V., Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokin. Biopharm. 21:1993;457-478.
5. Dingemanse J., Danhof M., Breimer D.D. Pharmacokinetic pharmacodynamic modeling of CNS drug effects. An overview. Pharmacol. Ther. 38:1988;1-52.
6. Ebling W.F., Danhof M., Stanski D.R. Pharmacodynamic characterization of the electroencephalographic effects of thiopental in rats. J. Pharmacokin. Biopharm. 19:1991;123-143.
7. File S.E., Pellow S. No cross-tolerance between the stimulatory and depressant actions of benzodiazepines in mice. Behav. Brain Res. 17:1985;1-7.
8. Flaherty C.F., Clarke S., Coppotelli C. Lack of tolerance to contrast-reducing actions of chlordiazepoxide with repeated reward reductions. Physiol. Behav. 60:1996;645-652.
9. Greenblatt M.D., Shader R.I. Long-term administration of benzodiazepines: pharmacokinetic versus pharmacodynamic tolerance. Psychopharmacol. Bull. 22:1986;416-423.
10. Griffiths J.W., Goudie A.J. Analysis of the role of behavioral factors in the development of tolerance to the benzodiazepine midazolam. Neuropharmacology. 26:1987;201-209.
11. Haefely W., Kyburz E., Gerecke M., Mohler H. Recent advances in the molecular pharmacology of benzodiazepine receptors. Adv. Drug Res. 14:1985;165-322.
12. Jusko W.J., Ko H.C. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56:1994;406-419.
13. Kaplan G.B., Tai N.T., Greenblatt D.J., Shader R.I. Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo. Psychopharmacology. 101:1990;539-544.
14. Lau C.E., Heatherington A. Pharmacokinetic-pharmacodynamic modeling of stimulatory and sedative effects of alprazolam: timing performance deficits. J. Pharmacol. Exp. Ther. 283:1997;1119-1129.
15. Lau C.E., Wang J. Alprazolam, caffeine and their interaction: relating DRL performance to pharmacokinetics. Psychopharmacology. 126:1996;115-124.
16. Lau C.E., Ma F., Wang Y., Smith C. Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. Psychopharmacology. 126:1996;241-248.
17. Lau C.E., Wang Y., Falk J.L. Differential reinforcement of low rate performance, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling: independent interaction of alprazolam and independent interaction of alprazolam and caffeine. J. Pharmacol. Exp. Ther. 281:1997;1013-1029.
18. Lau C.E., Wang Y., Falk J.L. Independent interaction of alprazolam and caffeine under chronic dose regimens on differential reinforcement of low rate (DRL 45-s) performance. Psychopharmacology. 134:1997;277-286.
19. Laurijssens B.E., Greenblatt D.J. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin. Pharmacokin. 30:1996;52-76.
20. Lopez F., Miller L.G., Greenblatt D.J., Paul S.M., Shader R.I. Low-dose alprazolam augments motor activity in mice. Pharmacol. Biochem. Behav. 30:1988;511-513.
21. Ma F., Lau C.E. Determination of midazolam and its metabolites in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats. J. Chromatogr. B. 682:1996;109-113.
22. Mandema J.W., Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis. J. Pharmacokin. Biopharm. 18:1990;459-481.
23. Mandema J.W., Tukker E., Danhof M. Pharmacokinetic-pharmacodynamic modeling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br. J. Pharmacol. 102:1991;663-668.
24. Mandema J.W., Tukker E., Danhof M. In vivo characterization of the pharmacoynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. J. Pharmacol. Exp. Ther. 260:1992;36-44.
25. Mandema J.W., Tukker E., Danhof M. In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. J. Pharmacol. Exp. Ther. 261:1992;56-61.
26. Miller L.G., Greenblatt D.J., Barnhill J.G., Deutsch S.I., Shader R.I., Paul S.M. Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J. Neurochem. 49:1987;1595-1601.
27. Paalzow L.K., Edlund P.O. Multiple receptor responses: a concept to describe the relationship between pharmacological effects and pharmacokinetics of a drug: studies on clonidine in the rat and cat. J. Pharmacokinet. Biopharm. 7:1979;495-510.
28. Pier L., Schooner R., Scherschlicht R., Polc P., Sepinwall J., Davidson A., Mohler H., Cumin R., Da Prada M., Burkard W.P., Keller H.H., Muller R.K.M., Gerold M., Pier M., Cook L., Haefely W. Pharmacology of midazolam. Arzneim-Forsch/Drug Res. 31:1981;2180-2201.
29. SAAM II User Guide 1997. SAAM Institute, University of Washington, Box 352255, Seattle, WA 98195.
30. Sansone M. Effect of repeated administration of chlordiazepoxide on spontaneous locomotor activity in mice. Psychopharmacology. 66:1979;109-110.
31. Sheiner L.B., Stanski D.R., Vozeh S., Miller R.D., Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin. Pharmacol. Ther. 25:1979;358-370.
32. Smith R.B., Kroboth P.D., Vanderlugt J.T., Phillips J.P., Juhl R.P. Pharmacokinetics and pharmacodynamics of alprazolam after oral and i.v. administration. Psychopharmacology. 84:1984;452-456.
33. Tang M., Lau C.E., Falk J.L. Midazolam and discriminative motor control: chronic administration, withdrawal and modulation by the antagonist Ro 15-1788. J. Pharmacol. Exp. Ther. 246:1988;1053-1060.
34. Venitz, J., 1995. Pharmacokinetic-pharmacodynamic modeling of reversible drug effects. In: Derendorf, H., Hochhaus, G. (Eds.), Handbook of Pharmacokinetic/Pharmacodynamic Correlation. CRC Press, Boca Raton, FL, pp. 1-34.
35. Venitz, J., Garnett, W.R., Slattum, P.W., Yong, C.L., 1990. Bradycardic effect of oxybutynin, an antimuscarinic compound, after oral administration to young and elderly healthy volunteers. 3rd Symposium Frontiers of Pharmacokinetics and Pharmacodynamics, Baltimore, MD, April 2-4.
36. Vgontzas A.N., Kales A., Bixler E.O. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology. 51:1995;205-223.